Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
Published in: | Health Technology Assessment |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Text |
Language: | English |
Published: |
NIHR Journals Library
2017
|
Subjects: | |
Online Access: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494513/ http://www.ncbi.nlm.nih.gov/pubmed/28628003 https://doi.org/10.3310/hta21280 |
Description not available. |